Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various ...

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

Biocon Biologics on Thursday said it has received an approval from the US health regulator to market a cancer treatment ...

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable ...

The US sales of bevacizumab were around $2 billion in 2023. Amgen, Amneal, Celltrion and Pfizer are its competitors in the US ...

The tripeptide glycyl-L-histidyl-L-lysine (GHK), when complexed with copper ions to form GHK-Cu, has garnered attention for ...

NexThera Co., Ltd. (CEO:SaeGwang Park) announced on April 9th that it has completed the first patient enrollment for its Phase 1/2a clinical trial of NT-101, a novel eye drop treatment for wet AMD, at ...

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global ...

Several transcription factors in developing neurons exhibit broad-to-restricted expression patterns, but the relevance of ...